The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing's syndrome

European Journal of Endocrinology

Volumn 165, Issue 6, 2011, Pages 865-871

  Świa̧tkowska Stodulska, Renata ^a   Kaniuka Jakubowska, Sonia ^a   Wisńiewski, Piotr ^a   Skibowska Bielinśka, Anna ^a   Sworczak, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; FIBRINOGEN; HYDROCORTISONE; PROTEIN C; PROTEIN S; THROMBOMODULIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING PARAMETERS; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; CUSHING SYNDROME; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; CROSS-SECTIONAL STUDIES; CUSHING SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN C; PROTEIN S; THROMBOEMBOLISM; THROMBOMODULIN;

EID: 81555210917     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0535     Document Type: Article

References (45)

1. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM & Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3662-3666. (doi:10.1210/jc.87.8.3662)
2. Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S & Kickler TS. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thrombosis Research 2006 118 247-452. (doi:10.1016/j.thromres.2005. 06.006)
3. Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P & Blann AD. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thrombosis and Haemostasis 2005 94 797-801. (doi:10.1160/ TH04-10-0652)
4. Jacoby RC, Owings JT, Ortega T, Gosselin R & Feldman EC. Biochemical basis for the hypercoagulable state seen in Cushing syndrome. Archives of Surgery 2001 136 1003-1006. (doi:10. 1001/archsurg.136.9.1003)
5. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Büller HR & Brandjes DP. Hypercoagulable state in Cushing's syndrome: a systematic review. Journal of Clinical Endocrinology and Metabolism 2009 94 2743-2750. (doi:10. 1210/jc.2009-0290)
6. Kastelan D, Dusek T, Kraljevic I, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I & Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrynolytic markers. Endocrine 2009 36 70-74. (doi:10.1007/s12020-009- 9186-y)
7. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A & Martino E. Changes in coagulation indexes and occurrence of venous thromboembolismin patients with Cushing's syndrome: results from a prospective study before and after surgery. European Journal of Endocrinology 2010 163 783-791. (doi:10.1530/EJE-10-0583)
8. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S & Girolami A. Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thrombosis and Haemostasis 1985 54 518-520. (Pubitemid 16255686)
9. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M & Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagulation & Fibrinolysis 1992 3 789-793. (doi:10.1097/00001721-199212 000-00013)
10. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S & Girolami A. Abnormalities of vonWillebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagulation & Fibrinolysis 1999 10 145-151. (doi:10.1097/ 00001721-199904000-00006)
11. Fatti LM, Botasso B, Invitti C, Coppola R, Cavagnini F & Mannucci PM. Markers of activation of coagulation and fibrinolysis in patient with Cushing's syndrome. Journal of Endocrinological Investigation 2000 23 145-150. (Pubitemid 30218782)
12. Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W & Goldschmidt P. Hemostatic effects of stress hormone infusion. Anesthesiology 1994 81 1116-1126. (doi:10.1097/00000542- 199411000-00005)
13. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O & Onder Ersoz H. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. Journal of Endocrinological Investigation 2009 32 169-174.
14. Juhan-Vague I, Alessi MC, Mavri A & Morange PE. Plasminogen activator-1, inflammation, obesity, insulin resistance and vascular risk. Journal of Thrombosis and Haemostasis 2003 1 1575-1579. (doi:10.1046/j.1538- 7836.2003.00279.x)
15. Terzolo M, Reimondo G, Bovio S & Angeli A. Subclinical Cushing's syndrome. Pituitary 2004 7 217-223. (doi:10.1007/s11102- 005-4024-6)
16. Caetano MS, Silva Rdo C & Kater CE. Increased diagnostic probability of subclinical Cushing's syndrome in a population sample of overweight adult patients with type 2 diabetes mellitus. Arquivos Brasileiros de Endocrinologia e Metabologia 2007 51 1118-1127. (doi:10.1590/S0004-2730200700070 0015)
17. Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G & Angeli A. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinology and Metabolism Clinics of North America 2005 34 423-439. (doi:10.1016/j.ecl.2005.01. 008)
18. Terzolo M, Osella G, Alì A, Borretta G, Cesario F, Paccotti P & Angeli A. Subclinical Cushing's syndrome in adrenal incidentaloma. Clinical Endocrinology 1998 48 89-97. (doi:10.1046/j. 1365-2265.1998.00357.x)
19. Sworczak K, Babińska A, Stanek A, Lewczuk A, Siekierska- Hellman M, Błaut K, Drobińska A, Basinski A, Łachiński AJ, Czplińska-Kałas H & Gruca Z. Clinical and histopathological evaluation of the arenal incidentaloma. Neoplasma 2001 48 221-226.
20. Mazzuco TL, Bourdeau I & Lacroix A. Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment. Current Opinion in Endocrinology, Diabetes, and Obesity 2009 16 203-210. (doi:10.1097/MED. 0b013e32832b7043)
21. Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S & Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2002 87 4872-4878. (doi:10.1210/jc.2001-011766)
22. Nakagawa S. A farewell to Bonferroni: the problems of low statistical power and publication bias. Behavioral Ecology 2004 15 1044-1045. (doi:10.1093/beheco/arh107)
23. Ikkala E, Myllylä G, Pelkonen R, Rasi V, Viinikka L & Ylikorkala O. Haemostatic parameters in Cushing's syndrome. Acta Medica Scandinavica 1985 217 507-511. (doi:10.1111/j.0954-6820. 1985.tb03254.x)
24. Świa̧tkowska-Stodulska R, Babińska A & Sworczak K. Hypercortisolism and hemostasis. Polski Merkuriusz Lekarski 2009 26 142-144.
25. Świa̧tkowska-Stodulska R, Babińska A & Sworczak K. Effect of selected hormones on particular parameters of hemostasis. Wiadomosci Lekarskie 2007 60 390-393.
26. Kopeć M. Diverse and variable functions of thrombin. Acta Haematologica Polonica 1997 28 95-100.
27. Kopeć M. Progress in understanding mechanisms of blood coagulation activation. Acta Haematologica Polonica 1994 25 (Suppl 2) 5-13.
28. Zawilska K. Czynniki ryzyka zakrzepów tȩtniczych. In Zakrzepy i zatory, pp 141-151. Ed. S Łopaciuk, Warszawa (in Polish): Wydawnictwo Lekarskie PZWL, 1996.
29. Costallat LT, Ribeiro CC & Annichino-Bazzacchi JM. Antithrombin, protein S and protein C and antiphospholipid antibodies in systemic lupus erythematosus. Sangre 1998 43 345-348. (Pubitemid 128519553)
30. Séguin C, Abid R, Spokes KC & AirdWC. Thrombin downregulates thrombomodulin expression and activity in primary human endothelial cells. Endothelium 2008 15 143-148. (doi:10.1080/ 10623320802125508)
31. Jilma B, Blann AD, Stohlawetz P, Eichler HG, Kautzky-Willer A & Wagner OF. Dexamethasone lowers circulating E-selectin and ICAM-1 in healthy men. Journal of Laboratory and Clinical Medicine 2000 135 270-274. (doi:10.1067/mlc.2000. 105214)
32. Castoldi E & Rosing J. APC resistance: biological basis and aquired influences. Journal of Thrombosis and Haemostasis 2009 8 445-453. (doi:10.1111/j.1538-7836.2009.03711.x)
33. Soare AM & Popa C. Deficiencies of protein C, A and antithrombin and activated protein C reasistance-their involvement in the occurrence of arterial thromboses. Journal of Medicine and Life 2010 3 412-415.
34. Batist G, Bothe A Jr, Bern M, Bistrian BR & Blackburn GL. Low antithrombin III in morbid obesity: return to normal with weight reduction. Journal of Parenteral and Enteral Nutrition 1983 7 447-449. (doi:10.1177/ 0148607183007005447)
35. De Pergola G, De Mitrio V, Sciaraffia M, Pannacciulli N, Minenna A, Giorgino F, Petronelli M, Laudadio E & Giorgino R. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997 46 1287-1293. (doi:10.1016/S0026-0495(97)90232-8)
36. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L, Pannacciulli N & Giorgino R. Increase in both prothrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. International Journal of Obesity and Related Metabolic Disorders 1997 21 527-535. (doi:10.1038/sj.ijo.0800435)
37. Bowles LK, Cooper JA, Howarth DJ, Miller GJ & MacCallum PK. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagulation & Fibrinolysis 2003 14 569-573. (doi:10.1097/00001721-200309000-00009)
38. Rość D, Drewniak W, Kinasz-Rozycka I, Kulwas A & Michalski A. Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men. Polski Merkuriusz Lekarski 2003 15 518-520. (Pubitemid 38120678)
39. Świa̧tkowska-Stodulska R, Skibowska-Bielińska A, Bȩkowska A, Wiśniewski P & Sworczak K. Assessment of selected haemostatic parameters in obese patients. Endokrynologia Polska 2007 58 505-509.
40. Sumida Y, Wada H, Fujii M, Mori Y, Nakasaki T, Shimura M, Hiyoyama K, Yano Y, Deguchi K, Shiku H & Adachi Y. Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Blood Coagulation & Fibrinolysis 1997 8 303-307. (doi:10.1097/00001721-199707 000-00007)
41. Gabat S, Keller C, Kempe HP, Amiral J, Ziegler R, Ritz E, Bergis KH, Wahl P & Nawroth P. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. VASA. Zeitschrift für Gefässkrankheiten. Journal for VascularDiseases 1996 25 233-241.
42. Reverter JL, Reverter JC, Tàssies D, Rius F, Monteagudo J, Rubiés-Prat J, Escolar G, Ordinas A & Sanmarti A. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. American Journal of Hematology 1997 56 93-99. (doi:10.1002/(SICI)1096-8652(199710)56:2〈93::AID-AJH4〉3.0.CO;2- W)
43. Lengyel Z, Vörös P, Tóth LK, Németh C, Kammerer L, Mihály M, Tornóci L & Rosivall L. Urinary albumin excretion is correlated to fibrinogen levels and protein S activity in patients with type 1 diabetes mellitus without overt diabetic nephropathy. Wiener Klinische Wochenschrift 2004 116 240-245. (doi:10.1007/BF03041054)
44. Wojtkielewicz K, Urban M, Peczyńska J & Głowiń ska B. Is soluble thrombomodulin a molecular marker of endothelial cell injury in children and adolescents with arterial hypertension? Medycyna Wieku Rozwojowego 2006 10 893-902.
45. Tsuki M, Tanabe E, Takagi S, Naruse M & Takano K. Cardiovascular risk and their long-term clinical outcome in patients with subclinical cushing's syndrome. Endocrine Journal 2008 55 737-745. (doi:10.1507/endocrj.K07E-177)